First Online: 4 October 2018
: The International Workshop for Merkel Cell Carcinoma Research, which included activities related to the preparation of this Consensus Statement, was supported by funding from Bristol-Myers Squibb (BMS), EMD Serono, the US National Cancer Institute and the US National Institute of Arthritis and Musculoskeletal and Skin Diseases. J.C.B. has received honoraria from Amgen, Merck Serono and Pfizer; he has received advisory board honoraria from Amgen, CureVac, eTheRNA, Lytix, Merck Serono, Novartis, Rigontec and Takeda; and he has received research funding from Boehringer Ingelheim, BMS and Merck Serono. S.B. reports research funding to his institution (the University of Washington, WA, USA) from Merck, BMS, EMD Serono, ImmuneDesign, NantKwest and Oncosec. S.B. has received honoraria for participation in advisory boards from EMD Serono and Genentech. S.P.D. has received consulting and travel support from EMD Serono. J.K. and M.H. are full-time employees of EMD Serono. M.M. is a full-time employee of Foundation Medicine. P.N. is a consultant of EMD Serono and Merck and reports research funding to his institution (the University of Washington, WA, USA) from BMS and EMD Serono. G.R. is an advisory board member and/or consultant of EMD Serono and Pfizer and owns stocks in Regeneron and Syros Pharmaceuticals. M.R. has served on the advisory boards of Merck and Novartis. M.T.T. serves on the advisory boards of Novartis, Myriad Genetics and Seattle Genetics. R.T. has received honoraria from Merck Serono. D.M.T. is a full-time employee of MedImmune. M.K.K.W. serves on the advisory boards of EMD Serono, Merck and Pfizer. The other authors and consortia members declare no competing interests.